Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Accumulated Expenses (2016 - 2025)

Protalix BioTherapeutics has reported Accumulated Expenses over the past 11 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $1.6 million for Q4 2025, down 82.97% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (down 82.97% YoY), and the annual figure for FY2025 was $1.6 million, down 82.97%.
  • Accumulated Expenses for Q4 2025 was $1.6 million at Protalix BioTherapeutics, up from $745000.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for PLX hit a ceiling of $9.6 million in Q4 2024 and a floor of $511000.0 in Q4 2023.
  • Median Accumulated Expenses over the past 3 years was $1.5 million (2025), compared with a mean of $3.5 million.
  • Biggest five-year swings in Accumulated Expenses: surged 1772.41% in 2024 and later tumbled 82.97% in 2025.
  • Protalix BioTherapeutics' Accumulated Expenses stood at $511000.0 in 2023, then surged by 1772.41% to $9.6 million in 2024, then tumbled by 82.97% to $1.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $1.6 million (Q4 2025), $745000.0 (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.